A decade of adaptation: Regulatory contributions of the World Health Organization to the Global Action Plan for Influenza Vaccines (2006-2016).
Identifieur interne : 000916 ( Main/Exploration ); précédent : 000915; suivant : 000917A decade of adaptation: Regulatory contributions of the World Health Organization to the Global Action Plan for Influenza Vaccines (2006-2016).
Auteurs : Laszlo Palkonyay [Suisse] ; Hiba Fatima [Suisse]Source :
- Vaccine [ 1873-2518 ] ; 2016.
Descripteurs français
- KwdFr :
- Autorisation d'exercer, Facteurs temps, Flambées de maladies (), Grippe humaine (), Grippe humaine (épidémiologie), Humains, Industrie pharmaceutique (normes), Organisation mondiale de la santé, Saisons, Sous-type H1N1 du virus de la grippe A (immunologie), Sous-type H5N1 du virus de la grippe A (immunologie), Tranfert de technologie, Vaccins antigrippaux (normes).
- MESH :
- immunologie : Sous-type H1N1 du virus de la grippe A, Sous-type H5N1 du virus de la grippe A.
- normes : Industrie pharmaceutique, Vaccins antigrippaux.
- épidémiologie : Grippe humaine.
- Autorisation d'exercer, Facteurs temps, Flambées de maladies, Grippe humaine, Humains, Organisation mondiale de la santé, Saisons, Tranfert de technologie.
English descriptors
- KwdEn :
- Disease Outbreaks (prevention & control), Drug Industry (standards), Humans, Influenza A Virus, H1N1 Subtype (immunology), Influenza A Virus, H5N1 Subtype (immunology), Influenza Vaccines (standards), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Licensure, Seasons, Technology Transfer, Time Factors, World Health Organization.
- MESH :
- chemical , standards : Influenza Vaccines.
- epidemiology : Influenza, Human.
- immunology : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H5N1 Subtype.
- prevention & control : Disease Outbreaks, Influenza, Human.
- standards : Drug Industry.
- Humans, Licensure, Seasons, Technology Transfer, Time Factors, World Health Organization.
Abstract
The Global Action Plan (GAP) for Influenza Vaccines is a decade-long initiative that brings together a diverse range of stakeholders to work towards reducing anticipated global shortage of influenza vaccines and ensuring more equitable access to vaccines during the next influenza pandemic. Since its inception in 2006, significant progress has been made towards all the main objectives of GAP, namely: (1) an increase in seasonal vaccine use, (2) an increase in vaccine production, and (3) progress in research and development of more effective vaccines. The Technology Transfer Initiative (TTI), conceived and managed by WHO under the GAP, contributed to increasing regional influenza vaccine production capacity. This was achieved by facilitating technology transfer in 14 low- and middle-income countries, through grants to manufacturers to establish or strengthen influenza vaccine production capacity and support to their national regulatory authorities. Five of the countries subsequently licensed locally produced influenza vaccines; two pandemic and three seasonal vaccines received WHO prequalification. The success of GAP can be largely attributed to the regulatory support provided by WHO to both manufacturers and regulators. This support had two components: (1) direct regulatory support to GAP/TTI, and (2) support to GAP-related WHO programmes, such as the Pandemic Influenza Vaccine Deployment Initiative in 2010 and the Pandemic Influenza Preparedness Framework since 2013, especially in non-vaccine-producing countries. Temporary adaptation of the assessment process for influenza vaccines in the WHO Vaccine Prequalification Programme to the A(H1N1) pandemic situation in 2009 was instrumental to the success of the WHO Pandemic Influenza Vaccine Deployment Initiative in its attempt to meet the demand for pandemic vaccines in countries that received donated vaccines.
DOI: 10.1016/j.vaccine.2016.07.025
PubMed: 27498212
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000503
- to stream PubMed, to step Curation: 000503
- to stream PubMed, to step Checkpoint: 000538
- to stream Ncbi, to step Merge: 001B86
- to stream Ncbi, to step Curation: 001B86
- to stream Ncbi, to step Checkpoint: 001B86
- to stream Main, to step Merge: 000918
- to stream Main, to step Curation: 000916
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A decade of adaptation: Regulatory contributions of the World Health Organization to the Global Action Plan for Influenza Vaccines (2006-2016).</title><author><name sortKey="Palkonyay, Laszlo" sort="Palkonyay, Laszlo" uniqKey="Palkonyay L" first="Laszlo" last="Palkonyay">Laszlo Palkonyay</name><affiliation wicri:level="1"><nlm:affiliation>World Health Organization, 20 avenue Appia, 1211 Geneva, Switzerland. Electronic address: palkonyayl@who.int.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>World Health Organization, 20 avenue Appia, 1211 Geneva</wicri:regionArea><wicri:noRegion>1211 Geneva</wicri:noRegion></affiliation></author><author><name sortKey="Fatima, Hiba" sort="Fatima, Hiba" uniqKey="Fatima H" first="Hiba" last="Fatima">Hiba Fatima</name><affiliation wicri:level="1"><nlm:affiliation>World Health Organization, 20 avenue Appia, 1211 Geneva, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>World Health Organization, 20 avenue Appia, 1211 Geneva</wicri:regionArea><wicri:noRegion>1211 Geneva</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27498212</idno><idno type="pmid">27498212</idno><idno type="doi">10.1016/j.vaccine.2016.07.025</idno><idno type="wicri:Area/PubMed/Corpus">000503</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000503</idno><idno type="wicri:Area/PubMed/Curation">000503</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000503</idno><idno type="wicri:Area/PubMed/Checkpoint">000538</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000538</idno><idno type="wicri:Area/Ncbi/Merge">001B86</idno><idno type="wicri:Area/Ncbi/Curation">001B86</idno><idno type="wicri:Area/Ncbi/Checkpoint">001B86</idno><idno type="wicri:Area/Main/Merge">000918</idno><idno type="wicri:Area/Main/Curation">000916</idno><idno type="wicri:Area/Main/Exploration">000916</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A decade of adaptation: Regulatory contributions of the World Health Organization to the Global Action Plan for Influenza Vaccines (2006-2016).</title><author><name sortKey="Palkonyay, Laszlo" sort="Palkonyay, Laszlo" uniqKey="Palkonyay L" first="Laszlo" last="Palkonyay">Laszlo Palkonyay</name><affiliation wicri:level="1"><nlm:affiliation>World Health Organization, 20 avenue Appia, 1211 Geneva, Switzerland. Electronic address: palkonyayl@who.int.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>World Health Organization, 20 avenue Appia, 1211 Geneva</wicri:regionArea><wicri:noRegion>1211 Geneva</wicri:noRegion></affiliation></author><author><name sortKey="Fatima, Hiba" sort="Fatima, Hiba" uniqKey="Fatima H" first="Hiba" last="Fatima">Hiba Fatima</name><affiliation wicri:level="1"><nlm:affiliation>World Health Organization, 20 avenue Appia, 1211 Geneva, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>World Health Organization, 20 avenue Appia, 1211 Geneva</wicri:regionArea><wicri:noRegion>1211 Geneva</wicri:noRegion></affiliation></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Disease Outbreaks (prevention & control)</term><term>Drug Industry (standards)</term><term>Humans</term><term>Influenza A Virus, H1N1 Subtype (immunology)</term><term>Influenza A Virus, H5N1 Subtype (immunology)</term><term>Influenza Vaccines (standards)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Licensure</term><term>Seasons</term><term>Technology Transfer</term><term>Time Factors</term><term>World Health Organization</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Autorisation d'exercer</term><term>Facteurs temps</term><term>Flambées de maladies ()</term><term>Grippe humaine ()</term><term>Grippe humaine (épidémiologie)</term><term>Humains</term><term>Industrie pharmaceutique (normes)</term><term>Organisation mondiale de la santé</term><term>Saisons</term><term>Sous-type H1N1 du virus de la grippe A (immunologie)</term><term>Sous-type H5N1 du virus de la grippe A (immunologie)</term><term>Tranfert de technologie</term><term>Vaccins antigrippaux (normes)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="standards" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term><term>Sous-type H5N1 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza A Virus, H5N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="normes" xml:lang="fr"><term>Industrie pharmaceutique</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Disease Outbreaks</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Drug Industry</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Licensure</term><term>Seasons</term><term>Technology Transfer</term><term>Time Factors</term><term>World Health Organization</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Autorisation d'exercer</term><term>Facteurs temps</term><term>Flambées de maladies</term><term>Grippe humaine</term><term>Humains</term><term>Organisation mondiale de la santé</term><term>Saisons</term><term>Tranfert de technologie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The Global Action Plan (GAP) for Influenza Vaccines is a decade-long initiative that brings together a diverse range of stakeholders to work towards reducing anticipated global shortage of influenza vaccines and ensuring more equitable access to vaccines during the next influenza pandemic. Since its inception in 2006, significant progress has been made towards all the main objectives of GAP, namely: (1) an increase in seasonal vaccine use, (2) an increase in vaccine production, and (3) progress in research and development of more effective vaccines. The Technology Transfer Initiative (TTI), conceived and managed by WHO under the GAP, contributed to increasing regional influenza vaccine production capacity. This was achieved by facilitating technology transfer in 14 low- and middle-income countries, through grants to manufacturers to establish or strengthen influenza vaccine production capacity and support to their national regulatory authorities. Five of the countries subsequently licensed locally produced influenza vaccines; two pandemic and three seasonal vaccines received WHO prequalification. The success of GAP can be largely attributed to the regulatory support provided by WHO to both manufacturers and regulators. This support had two components: (1) direct regulatory support to GAP/TTI, and (2) support to GAP-related WHO programmes, such as the Pandemic Influenza Vaccine Deployment Initiative in 2010 and the Pandemic Influenza Preparedness Framework since 2013, especially in non-vaccine-producing countries. Temporary adaptation of the assessment process for influenza vaccines in the WHO Vaccine Prequalification Programme to the A(H1N1) pandemic situation in 2009 was instrumental to the success of the WHO Pandemic Influenza Vaccine Deployment Initiative in its attempt to meet the demand for pandemic vaccines in countries that received donated vaccines.</div></front></TEI><affiliations><list><country><li>Suisse</li></country></list><tree><country name="Suisse"><noRegion><name sortKey="Palkonyay, Laszlo" sort="Palkonyay, Laszlo" uniqKey="Palkonyay L" first="Laszlo" last="Palkonyay">Laszlo Palkonyay</name></noRegion><name sortKey="Fatima, Hiba" sort="Fatima, Hiba" uniqKey="Fatima H" first="Hiba" last="Fatima">Hiba Fatima</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000916 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000916 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27498212
|texte= A decade of adaptation: Regulatory contributions of the World Health Organization to the Global Action Plan for Influenza Vaccines (2006-2016).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27498212" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |